Neuland Laboratories (524558) Q3 24/25 earnings summary

Executive summary

• Q3FY25 total income rose 1.8% year-over-year to ₹401.9 crore, driven by Prime GDS and Specialty business, with marginal topline growth aligning with strategic initiatives in customer acquisition, capacity expansion, and process improvement.

• Revenues were led by key molecules in both CMS and GDS segments, with increased interest in peptides prompting new investments.

• Unaudited financial results for the quarter and nine months ended December 31, 2024, were approved by the Board on February 10, 2025.

• Both standalone and consolidated results were reviewed and found compliant with Indian Accounting Standards and SEBI regulations.

• Business remains uneven quarter-to-quarter due to the nature of CDMO and specialty GDS segments; annual evaluation is more accurate.

Financial highlights

• Q3FY25 total income was ₹401.9 crore, up 1.8% YoY; EBITDA was ₹90.3 crore (22.5% margin), down 26.4% YoY; Q3 gross margin was 53.2%, down from 59.8% in Q3 FY24.

• Q3FY25 profit after tax was ₹101.4 crore, including an exceptional gain of ₹55.8 crore from investment property sale.

• Nine-month revenue was ₹1,161.5 crore, a 1.7% decline year-over-year; EBITDA was ₹284.6 crore, down 21.5% YoY; PAT was ₹231.7 crore, nearly flat YoY, with ₹76.4 crore exceptional gain.

• Free cash flow for nine months was ₹70.8 crore; net debt position is negative ₹185.1 crore at Q3FY25 end.

• Basic and diluted EPS for Q3 FY25 were ₹79.18 (consolidated) and ₹79.03 (standalone), significantly higher than previous quarters.

Outlook and guidance

• FY25 is projected to be flat, with growth expected to resume in FY26 as new facilities and commercial molecules scale up.

• Management remains optimistic about medium- and long-term business momentum, citing strong customer traction and ongoing capacity enhancements, especially in peptides.

• Ongoing investments in capacity, especially in peptides, are expected to drive long-term growth.